Efficacy and safety of repaglinide and metformin combined in type 2 diabetes mellitus.

Trial Profile

Efficacy and safety of repaglinide and metformin combined in type 2 diabetes mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Repaglinide (Primary) ; Gliclazide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2009 Actual end date (Nov 2003) added as reported by ClinicalTrials.gov.
    • 06 May 2009 Planned number of patients changed from 340 to 324 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top